Results 11 to 20 of about 1,870 (108)

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. [PDF]

Mol Ther, 2012
Oncolytic viruses are generally designed to be cancer selective on the basis of a single genetic mutation. JX-594 is a thymidine kinase (TK) gene-inactivated oncolytic vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) and lac-Z transgenes that is designed to destroy cancer cells through replication-dependent cell lysis
Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.   +19 more
europepmc   +4 more sources

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. [PDF]

Mol Ther, 2011
JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In a phase 1 trial, JX-594 injection into hepatocellular carcinoma (HCC) was well-tolerated and associated with viral ...
Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K, Rintoul J, Falls T, Hickman T, Rhee BG, Bell JC, Kirn DH, Hwang TH.   +16 more
europepmc   +4 more sources

BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy [PDF]

Cancer Immunology, Immunotherapy
Background The therapeutic efficacy of oncolytic vaccinia virus (JX-594) has been demonstrated in metastatic clear cell renal cell carcinoma (ccRCC); however, only selected patients respond, and there are no predictive biomarkers for therapeutic response.
Jee Soo Park, Won Sik Jang, Myung Eun Lee, Jongchan Kim, Keunhee Oh, Namhee Lee, Won Sik Ham   +6 more
doaj   +2 more sources

Using Computer Modeling and Experimental Methods to Screen for Aptamers That Bind to the VV-GMCSF-LACT Virus [PDF]

Molecules
Oncolytic virotherapy is a promising approach for cancer treatment. However, when introduced into the body, the virus provokes the production of virus-neutralizing antibodies, which can reduce its antitumor effect.
Maya Dymova, Natalia Vasileva, Daria Malysheva, Alisa Ageenko, Irina Shchugoreva, Polina Artyushenko, Felix Tomilin, Anna S. Kichkailo, Elena Kuligina, Vladimir Richter   +9 more
doaj   +2 more sources

PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma [PDF]

Cancer Cell International
Background Although a combination of immune checkpoint inhibitors (ICIs) is recommended as the first line treatment option for metastatic renal cell carcinoma (mRCC), several immune-related adverse events (irAEs) occur, especially hepatitis.
Jee Soo Park, Myung Eun Lee, Jongchan Kim, Keunhee Oh, Namhee Lee, Minsun Jung, Won Sik Jang, Won Sik Ham   +7 more
doaj   +2 more sources

Oncolytic vaccinia virus JX-594 shows subtype-specific activity and candidate biomarkers in gastric cancer cell lines

Scientific Reports
Oncolytic vaccinia virus JX-594 (pexastimogene devacirepvec) selectively replicates in tumour cells and stimulates antitumour immunity; however, its therapeutic potential in gastric cancer (GC) has not been systematically evaluated.
Jee Hung Kim, YeLin Kim, Youkeun Shin, Inho Park, Woo Sun Kwon, Tae Soo Kim, Namhee Lee, Keunhee Oh, Chan Kim, Hei-Cheul Jeung, Sun Young Rha   +10 more
doaj   +2 more sources

Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment

Biomedicines, 2022
Immune checkpoint inhibitors and tyrosine kinase inhibitors are the first-line treatment for metastatic renal cell carcinoma (mRCC), but their benefits are limited to specific patient subsets. Here, we aimed to evaluate the therapeutic efficacy of JX-594
Jee Soo Park, Myung Eun Lee, Won Sik Jang, Jongchan Kim, Se Mi Park, Keunhee Oh, Namhee Lee, Won Sik Ham   +7 more
doaj   +1 more source

Oncolytic Vaccinia Virus Augments T Cell Factor 1-Positive Stem-like CD8⁺ T Cells, Which Underlies the Efficacy of Anti-PD-1 Combination Immunotherapy

Biomedicines, 2022
Oncolytic virotherapy has garnered attention as an antigen-agnostic therapeutic cancer vaccine that induces cancer-specific T cell responses without additional antigen loading.
Yun-Hui Jeon, Namhee Lee, Jiyoon Yoo, Solchan Won, Suk-kyung Shin, Kyu-Hwan Kim, Jun-Gyu Park, Min-Gang Kim, Hang-Rae Kim, Keunhee Oh, Dong-Sup Lee   +10 more
doaj   +1 more source

Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies

Journal for ImmunoTherapy of Cancer, 2023
Background Oncolytic virus immunotherapy has revolutionized cancer immunotherapy by efficiently inducing both oncolysis and systemic immune activation.
Dong-Sup Lee, Mi-Ju Park, Namhee Lee, Yun-Hui Jeon, Jiyoon Yoo, Suk-kyung Shin, Songyi Lee, Byung-Jin Jung, Yun-Kyoung Hong, Keunhee Oh   +9 more
doaj   +1 more source

Progress of oncolytic virotherapy for neuroblastoma

Frontiers in Pediatrics, 2022
As a neuroendocrine tumor derived from the neural crest, neuroblastoma (NB) is the most common extracranial solid tumor in children. The prognosis in patients with low- and intermediate-risk NB is favorable while that in high-risk patients is often ...
Xiao-Tong Chen, Shu-Yang Dai, Yong Zhan, Ran Yang, De-Qian Chen, Yi Li, En-Qing Zhou, Rui Dong   +7 more
doaj   +1 more source